Keywords
Last Name
Institution

Megan L. Shaw

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentMicrobiology
Address

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ortiz-Riaño E, Ngo N, Devito S, Eggink D, Munger J, Shaw ML, de la Torre JC, Martínez-Sobrido L. Inhibition of arenavirus by a3, a pyrimidine biosynthesis inhibitor. J Virol. 2014 Jan; 88(2):878-89.
      View in: PubMed
    2. Shaw ML, Klumpp K. Successes and challenges in the antiviral field. Curr Opin Virol. 2013 Oct; 3(5):483-6.
      View in: PubMed
    3. Beyleveld G, White KM, Ayllon J, Shaw ML. New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions. Antiviral Res. 2013 Oct; 100(1):120-32.
      View in: PubMed
    4. Alamares-Sapuay JG, Martinez-Gil L, Stertz S, Miller MS, Shaw ML, Palese P. Serum- and glucocorticoid-regulated kinase 1 is required for nuclear export of the ribonucleoprotein of influenza A virus. J Virol. 2013 May; 87(10):6020-6.
      View in: PubMed
    5. Martínez-Gil L, Goff PH, Hai R, García-Sastre A, Shaw ML, Palese P. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol. 2013 Feb; 87(3):1290-300.
      View in: PubMed
    6. Martínez-Gil L, Ayllon J, Ortigoza MB, García-Sastre A, Shaw ML, Palese P. Identification of small molecules with type I interferon inducing properties by high-throughput screening. PLoS One. 2012; 7(11):e49049.
      View in: PubMed
    7. Ortigoza MB, Dibben O, Maamary J, Martinez-Gil L, Leyva-Grado VH, Abreu P, Ayllon J, Palese P, Shaw ML. A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. PLoS Pathog. 2012; 8(4):e1002668.
      View in: PubMed
    8. Shaw ML. The host interactome of influenza virus presents new potential targets for antiviral drugs. Rev Med Virol. 2011 Nov; 21(6):358-69.
      View in: PubMed
    9. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A. 2011 Apr 5; 108(14):5777-82.
      View in: PubMed
    10. Stertz S, Shaw ML. Uncovering the global host cell requirements for influenza virus replication via RNAi screening. Microbes Infect. 2011 May; 13(5):516-25.
      View in: PubMed
    11. Seto J, Qiao L, Guenzel CA, Xiao S, Shaw ML, Hayot F, Sealfon SC. Novel Nipah virus immune-antagonism strategy revealed by experimental and computational study. J Virol. 2010 Nov; 84(21):10965-73.
      View in: PubMed
    12. König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, García-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. Human host factors required for influenza virus replication. Nature. 2010 Feb 11; 463(7282):813-7.
      View in: PubMed
    13. Shaw ML. Henipaviruses employ a multifaceted approach to evade the antiviral interferon response. Viruses. 2009 Dec; 1(3):1190-203.
      View in: PubMed
    14. Ciancanelli MJ, Volchkova VA, Shaw ML, Volchkov VE, Basler CF. Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism. J Virol. 2009 Aug; 83(16):7828-41.
      View in: PubMed
    15. Kulkarni S, Volchkova V, Basler CF, Palese P, Volchkov VE, Shaw ML. Nipah virus edits its P gene at high frequency to express the V and W proteins. J Virol. 2009 Apr; 83(8):3982-7.
      View in: PubMed
    16. Hoffmann HH, Palese P, Shaw ML. Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res. 2008 Nov; 80(2):124-34.
      View in: PubMed
    17. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. PLoS Pathog. 2008 Jun; 4(6):e1000085.
      View in: PubMed
    18. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol. 2006 Jun; 80(11):5156-67.
      View in: PubMed
    19. Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF. Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J Virol. 2005 May; 79(10):6078-88.
      View in: PubMed
    20. Shaw ML, García-Sastre A, Palese P, Basler CF. Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol. 2004 Jun; 78(11):5633-41.
      View in: PubMed
    21. Shaw ML, McLauchlan J, Mills PR, Patel AH, McCruden EA. Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins. J Med Virol. 2003 Jul; 70(3):361-72.
      View in: PubMed
    22. Park MS, Shaw ML, Muñoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, García-Sastre A, Basler CF. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol. 2003 Jan; 77(2):1501-11.
      View in: PubMed
    Shaw's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067